C&O is pleased to be appointed by Shantou Meiji Pharmaceutical Co., Ltd., a subsidiary of Tokyo-listed Meiji Seika Kaisha, Ltd. (“Meiji Seika Kaisha”), as the distributor of its new-generation cephalosporin, Meiact.

This five-year distribution agreement, starting from January 1, 2008, is a strong testament to the strength of C&O and demonstrates the recognition of the company by key players in the pharmaceutical industry. 

Prior to the appointment of C&O as its distributor in China, the China sales force of Meiji Seika Kaisha had already placed Meiact in the market in China.